22 September 2026
Mayer Brown represents underwriters on Teva Pharmaceutical’s US$4.9 billion senior notes offering.
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| David Becker Lead | Mayer Brown | Partner | High Yield and Leveraged Finance | London |
| Rob Mathews Lead | Mayer Brown | Partner | High Yield and Leveraged Finance | London |
| Ben Bierwirth Lead | Mayer Brown | Partner | High Yield and Leveraged Finance | London |
| Fani Chlampoutaki | Mayer Brown | Senior associate | Not stated | Not stated |
| Henninger "Hank" Bullock | Mayer Brown | Not stated | Not stated | New York |
| Britt Miller | Mayer Brown | Not stated | Not stated | Chicago |
| Remmelt Reigersman | Mayer Brown | Not stated | Not stated | Palo Alto |
| Alexandra Newsom | Mayer Brown | Not stated | Not stated | San Francisco/Palo Alto |
Stated terms
- Stated value
- USD 4.90bn (US$4.9 billion)
- What the figure measures
- Issue size
- Client
- underwritersUnderwriters
- Counterparties
- Teva Pharmaceutical (Issuer)